Literature DB >> 15367334

Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma.

Jian Yu1, Hongyu Zhang, Jun Gu, Song Lin, Junhua Li, Wei Lu, Yifei Wang, Jingde Zhu.   

Abstract

BACKGROUND: Astrocytoma is a common aggressive intracranial tumor and presents a formidable challenge in the clinic. Association of altered DNA methylation patterns of the promoter CpG islands with the expression profile of cancer-related genes, has been found in many human tumors. Therefore, DNA methylation status as such may serve as an epigenetic biomarker for both diagnosis and prognosis of human tumors, including astrocytoma.
METHODS: We used the methylation specific PCR in conjunction with sequencing verification to establish the methylation profile of the promoter CpG island of thirty four genes in astrocytoma tissues from fifty three patients (The WHO grading: I: 14, II: 15, III: 12 and IV: 12 cases, respectively). In addition, compatible tissues (normal tissues distant from lesion) from three non-astrocytoma patients were included as the control.
RESULTS: Seventeen genes (ABL, APC, APAF1, BRCA1, CSPG2, DAPK1, hMLH1, LKB1, PTEN, p14ARF, p15INK4b, p27KIP1, p57KIP2, RASSF1C, RB1, SURVIVIN, and VHL) displayed a uniformly unmethylated pattern in all the astrocytoma and non-astrocytoma tissues examined. However, the MAGEA1 gene that was inactivated and hypermethylated in non-astrocytoma tissues, was partially demethylated in 24.5% of the astrocytoma tissues (co-existence of the hypermethylated and demethylated alleles). Of the astrocytoma associated hypermethylated genes, the methylation pattern of the CDH13, cyclin a1, DBCCR1, EPO, MYOD1, and p16INK4a genes changed in no more than 5.66% (3/53) of astrocytoma tissues compared to non-astrocytoma controls, while the RASSF1A, p73, AR, MGMT, CDH1, OCT6, MT1A, WT1, and IRF7 genes were more frequently hypermethylated in 69.8%, 47.2%, 41.5%, 35.8%, 32%, 30.2%, 30.2%, 30.2% and 26.4% of astrocytoma tissues, respectively. Demethylation mediated inducible expression of the CDH13, MAGEA1, MGMT, p73 and RASSF1A genes was established in an astrocytoma cell line (U251), demonstrating that expression of these genes is likely regulated by DNA methylation. AR gene hypermethylation was found exclusively in female patients (22/27, 81%, 0/26, 0%, P < 0.001), while the IRF7 gene hypermethylation preferentially occurred in the male counterparts (11/26, 42.3% to 3/27, 11%, P < 0.05). Applying the mathematic method "the Discovery of Association Rules", we have identified groups consisting of up to three genes that more likely display the altered methylation patterns in concert in astrocytoma.
CONCLUSIONS: Of the thirty four genes examined, sixteen genes exhibited astrocytoma associated changes in the methylation profile. In addition to the possible pathological significance, the established concordant methylation profiles of the subsets consisting of two to three target genes may provide useful clues to the development of the useful prognostic as well as diagnostic assays for astrocytoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367334      PMCID: PMC520749          DOI: 10.1186/1471-2407-4-65

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  66 in total

1.  DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms.

Authors:  H Yin; K L Blanchard
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

2.  BRCA1 and E-cadherin promoter hypermethylation and gene inactivation in cancer-association or mechanism?

Authors:  E R Fearon
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

3.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.

Authors:  M S Soengas; P Capodieci; D Polsky; J Mora; M Esteller; X Opitz-Araya; R McCombie; J G Herman; W L Gerald; Y A Lazebnik; C Cordón-Cardó; S W Lowe
Journal:  Nature       Date:  2001-01-11       Impact factor: 49.962

4.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.

Authors:  M Toyota; M Ohe-Toyota; N Ahuja; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

5.  DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis.

Authors:  M Esteller; M F Fraga; M Guo; J Garcia-Foncillas; I Hedenfalk; A K Godwin; J Trojan; C Vaurs-Barrière; Y J Bignon; S Ramus; J Benitez; T Caldes; Y Akiyama; Y Yuasa; V Launonen; M J Canal; R Rodriguez; G Capella; M A Peinado; A Borg; L A Aaltonen; B A Ponder; S B Baylin; J G Herman
Journal:  Hum Mol Genet       Date:  2001-12-15       Impact factor: 6.150

6.  Suppression of metallothionein gene expression in a rat hepatoma because of promoter-specific DNA methylation.

Authors:  K Ghoshal; S Majumder; Z Li; X Dong; S T Jacob
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

7.  Aberrant promoter methylation of multiple genes in non-small cell lung cancers.

Authors:  S Zöchbauer-Müller; K M Fong; A K Virmani; J Geradts; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

8.  Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.

Authors:  K Ichimura; M B Bolin; H M Goike; E E Schmidt; A Moshref; V P Collins
Journal:  Cancer Res       Date:  2000-01-15       Impact factor: 12.701

9.  Methylation and mutational analysis of p27(kip1) in prostate carcinoma.

Authors:  A S Kibel; M Christopher; D A Faith; G S Bova; P J Goodfellow; W B Isaacs
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

10.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors:  M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman
Journal:  N Engl J Med       Date:  2000-11-09       Impact factor: 91.245

View more
  43 in total

1.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Authors:  Julien Laffaire; Sibille Everhard; Ahmed Idbaih; Emmanuelle Crinière; Yannick Marie; Aurelien de Reyniès; Renaud Schiappa; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Joëlle Thillet; François Ducray
Journal:  Neuro Oncol       Date:  2010-10-05       Impact factor: 12.300

Review 2.  Molecular epigenetics and genetics in neuro-oncology.

Authors:  Raman P Nagarajan; Joseph F Costello
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  The role of survivin in diagnosis, prognosis and treatment of breast cancer.

Authors:  Yong-Gang Lv; Fang Yu; Qing Yao; Jiang-Hao Chen; Ling Wang
Journal:  J Thorac Dis       Date:  2010-06       Impact factor: 2.895

4.  Frequent loss of heterozygosity encompassing the hMLH1 locus in low grade astrocytic tumors.

Authors:  Tapasya Srivastava; Kunzang Chosdol; Parthaprasad Chattopadhayay; Chitra Sarkar; Ashok K Mahapatra; Subrata Sinha
Journal:  J Neurooncol       Date:  2006-10-04       Impact factor: 4.130

5.  Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.

Authors:  Ali Zekri; Seyed H Ghaffari; Marjan Yaghmaie; Mehrdad Asghari Estiar; Kamran Alimoghaddam; Mohammad Hossein Modarressi; Ardeshir Ghavamzadeh
Journal:  Mol Neurobiol       Date:  2015-03-11       Impact factor: 5.590

6.  Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Authors:  K L Rankeillor; D A Cairns; C Loughrey; S C Short; P Chumas; A Ismail; A Chakrabarty; S E Lawler; P Roberts
Journal:  J Neurooncol       Date:  2014-02-20       Impact factor: 4.130

Review 7.  Epigenetics of neurological cancers.

Authors:  Shaun D Fouse; Joseph F Costello
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 8.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

9.  Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer.

Authors:  Chan H Han; Qingyi Wei; Karen K Lu; Zhensheng Liu; Gordon B Mills; Li-E Wang
Journal:  Int J Clin Exp Med       Date:  2009-10-31

Review 10.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.